RBC Capital Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $134

RBC Capital maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $135 to $134.

Benzinga · 11/06/2019 13:36

RBC Capital maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $135 to $134.